First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi

Angela Collarino, Renato A. Valdés Olmos, Peter A. Neijenhuis, Wietske C. Den Hartog, Frederik Smit, Lioe Fee De Geus-Oei, Lenka M. Pereira Arias-Bouda*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Scopus)
158 Downloads (Pure)


OBJECTIVE. The purpose of this study is to evaluate a new device using molecular breast imaging (MBI) for 99mTc-sestamibi-guided stereotactic lesion localization as a complementary biopsy tool.

MATERIALS AND METHODS. From December 2012 to May 2016, a total of 38 consecutive women (mean age, 59 years; range, 41-77 years) underwent 99mTc-sestamibi-guided biopsy using a new MBI-based device and were retrospectively reviewed. The biopsy modality used five steps: Stereotactic localization of the 99mTc-sestamibi-avid lesion, calculation of coordinates of the lesion location using dedicated software, placement of the needle, verification of the correct needle position, and tissue sampling with a vacuum-assisted device followed by placement of a radiologic marker at the biopsy site and ex vivo measurement of the biopsy specimens.

RESULTS. The procedure was technically successful in all 38 lesions. In all cases, biopsy samples were radioactive and adequate for histopathologic analysis. Nineteen lesions (50%) were found to be malignant, and the remaining lesions were found to be benign. The mean procedure time was 71 minutes (range, 44-112 minutes). The radiologic marker was successfully deployed in 37 lesions (97%). Two hematomas and three vasovagal reactions were observed.

CONCLUSION. Technetium-99m sestamibi-guided biopsy performed using a dedicated MBI-based device is technically feasible and represents a valuable complementary biopsy tool in breast lesion diagnosis.

Original languageEnglish
Pages (from-to)1367-1373
Number of pages7
JournalAmerican Journal of Roentgenology
Issue number6
Publication statusPublished - 1 Dec 2017


  • Tc-sestamibi
  • Breast cancer
  • Molecular breast imaging
  • Radioguided biopsy


Dive into the research topics of 'First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi'. Together they form a unique fingerprint.

Cite this